3rd Quarter Results

RNS Number : 5527H
CT Private Equity Trust PLC
25 November 2022
 

 

To: Stock Exchange

For immediate release:


25 November 2022

 

CT Private Equity Trust PLC

Quarterly results for the three months ended 30 September 2022 (unaudited)
 

· Net asset value of 711.75p per Ordinary Share reflecting a total return for the three months of 9.3 per cent for the Ordinary Shares

· Quarterly dividend of 6.62p per Ordinary Share to be paid on 31 January 2023

· Dividend yield of 6.3 per cent based on the period end share price (1).

· As at 30 September 2022 net debt was £23.7 million equivalent to a gearing level of 4.4%.

· Since the period end San Siro has been sold realising £34.9 million for the Company representing 8.9x cost and 90% IRR.

 

(1)  Calculated as dividends of 5.65p paid on 29 April 2022, 6.05p paid on 29 July 2022, 6.31p paid on 31 October 2022 and 6.62p payable on 31 January 2023, divided by the Company's share price of 390.00p as at 30 September 2022.

 

Manager's Review

 

Introduction

 

As at 30 September 2022 the net assets of the Company were £518.5 million giving a Net Asset Value ("NAV") per share of 711.75p, which taking into account the dividend of 6.05p paid on 29 July 2022, gives a total return of 9.3% for the quarter. The NAV total return over the nine-month period ended 30 September 2022 was 14.0%.

 

The share price total return for the quarter was -9.7% and -17.2% for the nine-month period ended 30 September 2022. The Company's shares have traded on a large discount to NAV which fails to reflect the underlying valuations.

 

At 30 September 2022 the Company had net debt of £23.7 million. The current net debt is around £32 million prior to the receipt of the proceeds from the sale of San Siro. The outstanding undrawn commitments are £192.8 million of which £25.7 million is to funds where the investment period has expired. The valuation has the usual time lag and is composed of approximately 20% September 2022 valuations and 80% June 2022 valuations.

 

A dividend of 6.31p was paid on 31 October 2022. In accordance with the Company's dividend policy the next dividend will be 6.62p which will be paid on 31 January 2023 to shareholders on the register on 6 January 2023, with an ex-dividend date of 5 January 2023.

 

New Investments

 

During the quarter two fund commitments, one secondary investment and three co-investments were made.

 

We have increased our commitment to healthcare specialist Apposite Healthcare III by £5 million bringing the total committed up to £10 million. The fund is half invested and progressing well. We have committed €8 million to Volpi III, which is the second of this Pan-European mid-market specialist's funds we have backed. £2.6 million was invested via a secondary purchase in Kurma Biofund, a life sciences fund managed from France. We have co-invested £7.9 million alongside The Rohatyn Group in Leader96, the Bulgaria based assembler of e-bikes. We have co-invested £5.1 million with Peloton in 123Dentist, a Canada based chain of dental practices. We have also co-invested £2.3 million with MVM in Neurolens, a US developer of an innovative prismatic lens technology to diagnose and treat digital vision syndrome. There were two follow-on investments in co-investments this quarter both of which were to fund add-on acquisitions. £0.8 million was added to complex care company Orbis and £0.7 million was added to payments company Aurora Payment Solutions.

 

There were a number of new investments made by the funds in quite an active quarter. In the UK, August Equity V has been active, drawing £1.8 million for veterinary chain Medivet, a follow-on for high acuity care provider Orbis and cyber security specialist Cyber 360. FPE Fund III called £0.9 million for Dynamic Planner a leading software provider to the UK wealth management sector. Apiary called £0.4 million for MediaSense (technology enabled adviser to global corporations) and £0.3 million for LearnPro (virtual reality e-learning solutions for emergency services such as police, fire and rescue, health services, etc.). In Germany, DBAG VIII and VIIIB have together called £0.7 million for Freiheit, a pioneer in agile software development and an additional £0.7 million for Dantherm (climate control solutions) which we previously had exposure to through Procuritas V. In France and Italy, Chequers Capital XVII has been active with £1.3 million called for three new investments and one partial reinvestment; My Mobility (transportation for disabled children and adults in France), Somacis (complex printed circuit boards in Italy), Selini (equipment rental in Italy) and reinvestment of part of the proceeds from Serma (electronics testing).

 

Med Platform II called £0.8 million for California based Natus Medical (screening and diagnostics for neurological conditions).

 

The total of new investment drawn for co-investments and funds in the quarter was £32.5 million. Total new investment for the first nine months of the year is £69.8 million.  This is well balanced by total realisations of £79.6 million for the same period.

 

Realisations

 

There were a number of significant realisations during the quarter from both the funds and co-investment elements of the portfolio.

 

The largest realisation was from European buyout fund Volpi where we received a distribution of £7.4 million which was the proceeds from the sale of Irish IT managed services provider Version 1. This represents an excellent 5.9x cost and an IRR of 39%.

 

GCP Europe II, managed by Kester Capital, achieved a strong exit of contract research organisation Avania Clinical which specialises in medical devices. £6.7 million was received representing 8.4x and an IRR of 46%. Our co-investment in RGI, the Italy based provider of software to the Insurance sector, was sold returning £3.6 million. This investment was led by Corsair Capital and achieved 1.6x and an IRR of 12%. There is scope for the return to improve through deferred consideration depending on the final exit proceeds when new owner CVC sells.

 

Part of our holding in energy services company Ashtead Technology, which is now listed on AIM, was sold down during the quarter returning £2.8 million.

 

Inflexion has had another active period for exits. From the various funds we have received £2.3 million from the sale of wealth management company Succession (3.4x, 20% IRR), £1.2 million from IT recruitment specialist K2 (5.0x, 36% IRR) and £0.9 million from Virgin Experience Days (23.7x, 64% IRR).

 

In the Nordics, Verdane Edda has returned £1.7 million from the sale of vitamin K2 producer Kappa Bioscience (4.3x, 80% IRR). Summa II also sold chemicals management software company EcoOnline returning £0.5 million. In France, Chequers Capital XVII exited electronics testing company Serma returning £0.8 million (2.4x, 32% IRR). Chequers rolled over some of the proceeds into the new Ardian led deal as noted above.

 

Lastly in Poland, Avalon MBO Fund II exited engineering and technical building services company Stangl Technik through a sale to Astorg returning £0.5 million (5.8x, 50% IRR).

 

This has been a strong quarter for realisations with a total of £31.9 million of proceeds, including associated income, received. This brings the total for the first nine months of the year to £79.6 million.

 

There have been further realisations following the quarter end most notably the exit of Italian funeral homes company San Siro which was sold by Augens Capital to French Infrastructure fund Antin on 10 November 2022. This exit was at a value of £34.9 million for the Company, 75% of this will be received in cash and 25% rolled into the new deal. This represents an uplift of £23.3 million on the previous carrying value and a return of 8.9x cost and an IRR of circa. 90%. The investment thesis of building a chain of funeral homes and adding other facilities such as crematoria has been followed very well and this has resulted in this exceptional outcome.

 

Valuation Changes

 

There have been numerous valuation changes over the quarter. These are mostly positive but there has been a sizeable minority of downgrades reflecting a range of pressures on the businesses internationally.

 

The largest uplift as noted above was the £23.3 million uplift for San Siro. There was a £3.9 million uplift for the holding in F&C European Capital Partners LP, which reflects the removal of the discount on purchase earlier in the year. The Company as the sole remaining LP will hold the assets until realisation and hence a discount to reflect an immediate liquidation value is no longer appropriate. August Equity Partners IV (+£2.7 million) is up reflecting an imminent realisation of ISO compliance services company AMTIVO at an excellent 8.0x cost. GCP Europe II (+£3.1 million) records a gain reflecting the sale of Avania Clinical. Other good uplifts have been recorded by Coretrax (+£0.9 million), Rosa Mexicano (+£0.9 million) and Corpfin IV (+£0.8 million).

 

Downgrades include Ambio Holdings (-£1.8 million) where despite an exit being widely anticipated in the press, MVM have used a lower valuation. Alessa (formerly known as Tier I CRM) has been reduced by £1.4 million as the company has had a major change of focus with the exit of the original CRM business. Amethyst Radiotherapy is down by £0.6 million with the manager using a lower valuation multiple. Other downgrades include Agilitas 2015 (-£0.9 million), Procuritas IV (-£0.8 million) and DBAG VII (-£0.5 million).

 

Financing

 

The Company is currently modestly geared and this will reduce significantly on receipt of the San Siro proceeds. Most of the borrowing facility remains available and the facility is in place until June 2024. The cost of borrowing is increasing but moderate gearing should still enhance shareholder returns over the medium and longer term. The total of outstanding commitments remains within a manageable band. Realisations are likely to come in below the record-breaking total for 2021 but given the continuing strong run of exits the total will be very healthy.

 

Outlook

 

Reports from the funds and co-investments are increasingly reflecting the pressures which many investee companies are facing. These include general inflation, energy price rises and supply chain issues to name a few. Demand in most areas, outside certain consumer facing sectors, remains robust and many companies are continuing to benefit from some post Covid catch up. Confidence levels within the private equity sector and most of their underlying companies remains good and this is manifested in strong deal pipelines. In the tech-enabled area, which has proved very popular with private equity in recent years, there has been a shift in buying interest towards fast growing companies which are already profitable in preference to those with revenue growth but without current profitability. In this regard our portfolio is well positioned. The high degree of diversification across the portfolio, which spans the mid-market sector across Europe and further afield, also continues to be a distinct strength. As we approach the end of 2022, we have confidence that the Company will continue to build value for shareholders over the medium and longer term.

 

Hamish Mair

Investment Manager

Columbia Threadneedle Investment Business Limited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Portfolio Summary

Text Box: Portfolio Distribution As at 30 September 2022 % of Total 30 September 2022 % of Total 31 December 2021 Buyout Funds – Pan European* 9.4 9.6 Buyout Funds – UK 16.0 19.4 Buyout Funds – Continental Europe† 18.6 19.8 Secondary Funds 0.1 0.3 Private Equity Funds – USA 4.6 4.0 Private Equity Funds – Global 0.3 0.6 Venture Capital Funds 3.7 2.9 Direct – Quoted 0.9 0.1 Direct – Investments/Co-investments 46.4 43.3 100.0 100.0 * Europe including the UK. † Europe excluding the UK.

 

 

 

Ten Largest Holdings

As at 30 September 2022

Total Valuation £'000

% of Total Portfolio

San Siro

34,907

6.4

Inflexion Strategic Partners

19,295

3.5

Sigma

18,006

3.3

TWMA

14,154

2.6

Coretrax

12,950

2.4

Aliante Equity 3

11,225

2.0

Weird Fish

10,770

2.0

August Equity Partners IV

10,657

2.0

Bencis V

10,352

1.9

Aurora Payment Solutions

9,673

1.8

151,989

27.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Portfolio Holdings

 

Investment

Geographic Focus

 

Total

Valuation

£'000

% of Total Portfolio

 

Buyout Funds - Pan European




 

Apposite Healthcare II

Europe

8,625

1.6

 

F&C European Capital Partners

Europe

8,474

1.6

 

Stirling Square Capital II

Europe

6,747

1.2

 

Apposite Healthcare III

Europe

5,834

1.1

 

Volpi Capital

Northern Europe

5,808

1.1

 

Agilitas 2015 Fund

Northern Europe

4,754

0.9

 

ArchiMed II

Western Europe

4,384

0.8

 

Astorg VI

Western Europe

3,535

0.6

 

Silverfleet European Dev Fund

Europe

1,860

0.3

 

Med Platform II

Global

869

0.2

 

TDR II Annex Fund

Western Europe

235

-

 

TDR Capital II

Western Europe

211

-

 

ArchiMed MED III

Global

201

-

 

Agilitas 2020 Fund

Europe

29

-

 

Total Buyout Funds - Pan European


51,566

9.4

 

 

Buyout Funds - UK




 

Inflexion Strategic Partners

United Kingdom

19,295

3.5

 

August Equity Partners IV

United Kingdom

10,657

2.0

 

August Equity Partners V

United Kingdom

5,280

1.0

 

Apiary Capital Partners I

United Kingdom

5,046

0.9

 

Piper Private Equity VI

United Kingdom

4,611

0.8

 

Inflexion Supplemental V

United Kingdom

4,508

0.8

 

Inflexion Buyout Fund V

United Kingdom

4,039

0.7

 

Inflexion Buyout Fund IV

United Kingdom

3,501

0.6

 

Kester Capital II

United Kingdom

3,118

0.6

 

Inflexion Partnership Capital II

United Kingdom

2,744

0.5

 

RJD Private Equity Fund III

United Kingdom

2,733

0.5

 

Inflexion Enterprise Fund IV

United Kingdom

2,519

0.5

 

FPE Fund II

United Kingdom

2,474

0.5

 

Dunedin Buyout Fund II

United Kingdom

2,310

0.4

 

Horizon Capital 2013

United Kingdom

1,938

0.4

 

FPE Fund III

United Kingdom

1,799

0.3

 

Inflexion Enterprise Fund V

United Kingdom

1,773

0.3

 

Inflexion Partnership Capital I

United Kingdom

1,764

0.3

 

Inflexion 2012 Co-Invest Fund

United Kingdom

1,734

0.3

 

Inflexion Supplemental IV

United Kingdom

1,434

0.3

 

Primary Capital IV

United Kingdom

1,314

0.2

 

Piper Private Equity V

United Kingdom

1,108

0.2

 

GCP Europe II

United Kingdom

1,001

0.2

 

Inflexion 2010 Fund

United Kingdom

916

0.2

 

Inflexion Buyout Fund VI

United Kingdom

168

-

 

Piper Private Equity VII

United Kingdom

32

-

 

August Equity Partners III

United Kingdom

2

-

 

Total Buyout Funds - UK


87,818

16.0

 



 

 

 

 





 





 

Investment

Geographic Focus

 

Total

Valuation £'000

% of Total Portfolio

 

Buyout Funds - Continental Europe




 

Aliante Equity 3

Italy

11,225

2.0

 

Bencis V

Benelux

10,352

1.9

 

Chequers Capital XVII

France

5,947

1.1

 

DBAG VII

DACH

5,229

1.0

 

Vaaka III

Finland

5,210

0.9

 

Corpfin Capital Fund IV

Spain

5,059

0.9

 

Capvis III CV

DACH

5,023

0.9

 

Montefiore IV

France

4,213

0.8

 

Procuritas VI

Nordic

4,133

0.8

 

ARX CEE IV

Eastern Europe

3,993

0.7

 

Italian Portfolio

Italy

3,862

0.7

 

Summa II

Nordic

3,728

0.7

 

Procuritas Capital IV

Nordic

3,497

0.6

 

Verdane Edda

Nordic

3,235

0.6

 

DBAG VIII

DACH

2,519

0.5

 

Capvis IV

DACH

2,427

0.4

 

Summa I

Nordic

2,299

0.4

 

Chequers Capital XVI

France

2,284

0.4

 

DBAG Fund VI

DACH

2,079

0.4

 

Avallon MBO Fund III

Poland

2,038

0.4

 

NEM Imprese III

Italy

1,924

0.3

 

Vaaka II

Finland

1,818

0.3

 

Montefiore V

France

1,528

0.3

 

Ciclad 5

France

1,100

0.2

 

Portobello Fund III

Spain

1,075

0.2

 

DBAG VIIB

DACH

1,037

0.2

 

Corpfin V

Spain

874

0.2

 

Ciclad 4

France

813

0.1

 

Vaaka IV

Finland

761

0.1

 

PineBridge New Europe II

Eastern Europe

651

0.1

 

Avallon MBO Fund II

Poland

633

0.1

 

DBAG VIIIB

DACH

490

0.1

 

Procuritas VII

Nordic

459

0.1

 

DBAG Fund V

DACH

364

0.1

 

Procuritas Capital V

Nordic

360

0.1

 

Gilde Buyout Fund III

Benelux

92

-

 

N+1 Private Equity Fund II

Iberia

64

-

 

Capvis III

DACH

51

-

 

Summa III

Northern Europe

(123)

-

 

Total Buyout Funds - Continental Europe


102,323

18.6

 





 





 

 

 

 

 

 




Total Private Equity Funds - USA

Blue Point Capital IV

North America

8,672

1.6

Graycliff III

United States

4,475

0.8

Camden Partners IV

United States

3,309

0.6

Blue Point Capital III

North America

3,110

0.6

Stellex Capital Partners

North America

2,853

0.5

Graycliff IV

North America

2,106

0.4

HealthpointCapital Partners III

United States

534

0.1

Blue Point Capital II

North America

269

-

Total Private Equity Funds - USA


25,328

4.6

 




 




Private Equity Funds - Global




F&C Climate Opportunity Partners

Global

868

0.2

PineBridge GEM II

Global

765

0.1

AIF Capital Asia III

Asia

101

-

PineBridge Latin America II

South America

63

-

Warburg Pincus IX

Global

21

-

Total Private Equity Funds - Global


1,818

0.3

 

 

Venture Capital Funds




SEP V

United Kingdom

8,788

1.6

MVM V

Global

4,064

0.7

Kurma Biofund II

Europe

3,450

0.6

SEP IV

United Kingdom

1,480

0.3

Northern Gritstone

United Kingdom

1,000

0.2

Pentech Fund II

United Kingdom

658

0.1

Life Sciences Partners III

Western Europe

363

0.1

SEP II

United Kingdom

276

0.1

Alta Berkeley VI

Europe

64

-

Environmental Technologies Fund

Europe

63

-

SEP III

United Kingdom

44

-

Total Venture Capital Funds


20,250

3.7

 

 

Direct - Quoted




Ashtead

United Kingdom

4,190

0.8

Antero

Global

584

0.1

Laredo Petroleum

USA

31

-

Total Direct - Quoted


4,805

0.9

 

 

Secondary Funds




The Aurora Fund

Europe

371

0.1

Total Secondary Funds


371

0.1

 

 

 

 

 

 

 

Direct - Investments/Co-investments




San Siro

Italy

34,907

6.4

Sigma

United States

18,006

3.3

TWMA

United Kingdom

14,154

2.6

Coretrax

United Kingdom

12,950

2.4

Weird Fish

United Kingdom

10,770

2.0

Aurora Payment Solutions

United States

9,673

1.8

Jollyes

United Kingdom

8,646

1.6

AccuVein

United States

8,638

1.6

Leader96

Bulgaria

8,073

1.5

Ambio Holdings

United States

7,843

1.4

Swanton

United Kingdom

6,726

1.2

Rosa Mexicano

United States

6,702

1.2

Velos IoT (JT IoT)

United Kingdom

6,695

1.2

1Med

Switzerland

6,095

1.1

Avalon

United Kingdom

6,055

1.1

Orbis

United Kingdom

5,537

1.0

Amethyst Radiotherapy

Europe

5,419

1.0

Omlet

United Kingdom

5,277

1.0

123Dentist

Canada

5,216

1.0

ATEC (CETA)

United Kingdom

5,102

0.9

Cyberhawk

United Kingdom

5,016

0.9

Prollenium

North America

4,801

0.9

Contained Air Solutions

United Kingdom

4,790

0.9

Ashtead

United Kingdom

4,622

0.8

Dotmatics

United Kingdom

4,458

0.8

Alessa (Tier1 CRM)

Canada

4,110

0.7

Walkers Transport

United Kingdom

4,088

0.7

Perfect Image

United Kingdom

4,063

0.7

PathFactory

Canada

4,058

0.7

Habitus

Denmark

3,596

0.7

Agilico (DMC Canotec)

United Kingdom

3,480

0.6

Collingwood Insurance Group

United Kingdom

3,241

0.6

Bomaki

Italy

2,975

0.5

Babington

United Kingdom

2,929

0.5

Neurolens

United States

2,463

0.4

Vero Biotech

United States

1,547

0.3

Rephine

United Kingdom

1,417

0.3

Stone Computers

United Kingdom

282

0.1

Pet Network

Eastern Europe

110

-

TDR Algeco/Scotsman

Europe

62

-

Total Direct - Investments/Co-investments


254,592

46.4

Total Portfolio


548,871

100.0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CT PRIVATE EQUITY TRUST PLC

 

Statement of Comprehensive Income for the

nine months ended 30 September 2022 (unaudited)

 

 


 


Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Gains on investments held at fair value

-

71,703

71,703

Exchange losses

-

(1,757)

(1,757)

Investment income

3,971

-

3,971

Other income

121

-

121

Total income

4,092

69,946

74,038





Expenditure




Investment management fee - basic fee

(343)

(3,084)

(3,427)

Investment management fee - performance fee

-

(5,443)

(5,443)

Other expenses

(822)

-

(822)

Total expenditure

(1,165)

(8,527)

(9,692)





Profit before finance costs and taxation

2,927

61,419

64,346





Finance costs

(182)

(1,639)

(1,821)

 




Profit before taxation

2,745

59,780

62,525





Taxation

-

-

-





Profit for period/total comprehensive income

2,745

59,780

62,525

 




Return per Ordinary Share

3.73p

81.32p

85.05p

 




 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CT PRIVATE EQUITY TRUST PLC

 

Statement of Comprehensive Income for the

nine months ended 30 September 2021 (unaudited)

 


 

 


Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Gains on investments held at fair value

-

87,235

87,235

Exchange gains

-

2,790

2,790

Investment income

4,488

-

4,488

Other income

1

-

1

Total income

4,489

90,025

94,514





Expenditure




Investment management fee - basic fee

(283)

(2,550)

(2,833)

Investment management fee - performance fee

-

(4,427)

(4,427)

Other expenses

(744)

-

(744)

Total expenditure

(1,027)

(6,977)

(8,004)





Profit before finance costs and taxation

3,462

83,048

86,510





Finance costs

(193)

(1,738)

(1,931)

 




Profit before taxation

3,269

81,310

84,579





Taxation

-

-

-





Profit for period/total comprehensive income

3,269

81,310

84,579

 




Return per Ordinary Share

4.42p

109.97p

114.39p

 




 

 



CT PRIVATE EQUITY TRUST PLC

 

Statement of Comprehensive Income for the

year ended 31 December 2021 (audited)

 

 


 


Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Gains on investments held at fair value

-

128,313

128,313

Exchange gains

-

3,686

3,686

Investment income

6,719

-

6,719

Other income

3

-

3

Total income

6,722

131,999

138,721





Expenditure




Investment management fee - basic fee

(394)

(3,546)

(3,940)

Investment management fee - performance fee

-

(4,502)

(4,502)

Other expenses

(993)

-

(993)

Total expenditure

(1,387)

(8,048)

(9,435)





Profit before finance costs and taxation

5,335

123,951

129,286





Finance costs

(255)

(2,298)

(2,553)

 




Profit before taxation

5,080

121,653

126,733





Taxation

-

-

-





Profit for year/total comprehensive income

5,080

121,653

126,733

 




Return per Ordinary Share

6.87p

164.53p

171.40p

 




 

 



CT PRIVATE EQUITY TRUST PLC

 

Balance Sheet

 

 

 

 

As at 30 September 2022

As at 30 September 2021

As at 31 December

2021

 

(unaudited)

(unaudited)

(audited)

 

£'000

£'000

 '000

Non-current assets

 

 


Investments at fair value through profit or loss

548,871

448,007

483,047

 




Current assets




Other receivables

717

1,074

230

Cash and cash equivalents

14,062

37,098

32,702


14,779

38,172

32,932





Current liabilities




Other payables

(7,364)

(6,988)

(6,610)

Interest-bearing bank loan

(16,437)

(23,758)

(15,726)


(23,801)

(30,746)

(22,336)

Net current (liabilities)/assets

(9,022)

7,426

10,596

 




 




Interest-bearing bank loan

(21,373)

(20,613)

(20,196)

Net assets

518,476

434,820

473,447

 




Equity




Called-up ordinary share capital

728

739

739

Share premium account

2,527

2,527

2,527

Special distributable capital reserve

10,037

15,040

15,040

Special distributable revenue reserve

31,403

31,403

31,403

Capital redemption reserve

1,335

1,335

1,335

Capital reserve

472,446

383,776

422,403

Shareholders' funds

518,476

434,820

473,447





Net asset value per Ordinary Share

711.75p

588.06p

640.30p





 



CT PRIVATE EQUITY TRUST PLC

 

Reconciliation of Movements in Shareholders' Funds

 

 

 

 

 

Nine months ended

30 September

2022

Nine months ended

30 September 2021

Year

ended

31 December 2021

 

(unaudited)

(unaudited)

(audited)

 

£'000

£'000

£'000

Opening shareholders' funds

473,447

359,483

359,483

Buyback of ordinary shares

(5,014)

-

-

Profit for the period/total

comprehensive income

 

62,525

 

84,579

 

126,733

Dividends paid

(12,482)

(9,242)

(12,769)

 

Closing shareholders' funds

 

 

518,476 

 

434,820 

 

473,447

 

 


Notes (unaudited)

 

1.  The unaudited quarterly results have been prepared on the basis of the accounting policies set out in the statutory accounts of the Company for the year ended 31 December 2021.  Earnings for the nine months to 30 September 2022 should not be taken as a guide to the results for the year to 31 December 2022.

 

 

2.  Investment management fee:

 

 

 

Nine months ended

30 September 2022

  (unaudited)

 

 

Nine months ended

30 September 2021

  (unaudited)

 

 

Year ended

31 December 2021

   (audited)

 

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

 

 

 

 

 

 

 

 

 

 

Investment management  fee - basic fee

 

343

 

3,084

 

3,427

 

283

 

2,550

 

2,833

 

394

 

3,546

 

3,940

Investment management  fee - performance fee

 

-

 

5,443

 

5,443

 

-

 

4,427

 

4,427

 

-

 

4,502

 

4,502

 

 

343

 

8,527

 

8,870

 

283

 

6,977

 

7,260

 

394

 

8,048

 

8,442

 

 

 

 

 

 

 

 

 

 

 

3.  Finance costs:

 

 

 

Nine months ended

30 September 2022

  (unaudited)

 

 

Nine months ended

 30 September 2021

  (unaudited)

 

 

Year ended

31 December 2021

  (audited)

 

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

 

 

 

 

 

 

 

 

 

 

Interest payable on bank loans

182

1,639

1,821

193

1,738

1,931

255

2,298

2,553

 

 

 

 

 

 

 

 

 

 

 

4.  Returns and net asset values

 

   Nine months ended

30 September 2022

  (unaudited)

   Nine months ended

 30 September 2021

  (unaudited)

  Year ended

31 December 2021

  (audited)

The returns and net asset values per share are based on the following figures:

 

 

 

 

Revenue Return

£2,745,000

£3,269,000

£5,080,000

Capital Return

£59,780,000

£81,310,000

£121,653,000

Net assets attributable to shareholders

£518,476,000

£434,820,000

£473,447,000

Number of shares in issue at end of period (excluding shares held in treasury)

72,844,938

73,941,429

73,941,429

Weighted average number of shares in issue during the period

(excluding shares held in treasury)

73,509,913

73,941,429

73,941,429

 

 

 

 

 

 

 

 

5.  The financial information for the nine months ended 30 September 2022, which has not been audited or reviewed by the Company's auditor, comprises non-statutory accounts within the meaning of Section 434 of the Companies Act 2006.  Statutory accounts for the year ended 31 December 2021, on which the auditor issued an unqualified report, have been lodged with the Registrar of Companies.  The quarterly report is available on the Company's website www.ctprivateequitytrust.com

 

Legal Entity Identifier: 2138009FW98WZFCGRN66

 

For more information, please contact:

 

Hamish Mair (Investment Manager)

0131 718 1184

Scott McEllen (Company Secretary)

0131 718 1137

hamish.mair@columbiathreadneedle.com   / scott.mcellen@columbiathreadneedle.com



 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTPPGPCGUPPGQC
UK 100

Latest directors dealings